Wisconsin Chapter

We’re Still Here for You!

The Alzheimer’s Association takes pride in being a community-based, community-focused organization. Following the newest advisory from the Centers for Disease Control and Prevention (CDC), the Wisconsin Chapter, out of abundance of caution, is postponing our plans to return to the office.

Care and Support offerings – including some Education Programs and Support Groups – are transitioning back to in-person meetings, following local public health guidelines. We ask for your patience as some transitions take time, depending on meeting location requirements. We will continue to offer virtual and on-demand options.

We are also excited that the Walk to End Alzheimer’s will be in-person in Wisconsin, with 27 Walks across our great state. This is the world’s largest event to raise awareness and funds for Alzheimer’s care, support and research. Join us: alz.org/walk

Please call our 24/7 Helpline at 800.272.3900 for reliable information and support including the most up-to-date information on program opportunities in your area.

Resources

Currently, over 120,000 people in Wisconsin are living with Alzheimer's or dementia, and more than 196,000 people care for loved ones with the disease. We are here to serve the families in Wisconsin so that no one has to face this disease alone. The Alzheimer’s Association is available to you through our 24/7 Helpline: 800.272.3900

Serving the state of Wisconsin, the Association provides reliable information and care consultation; supportive services for families; educational opportunities; funding for dementia research; and advocacy efforts for public policy changes across the state.

• Wisconsin Alzheimer's Statistics
• Wisconsin Chapter Overview
• September Virtual Education Classes
• October Education Classes
• Support Groups

Wisconsin locations:  
Milwaukee – 414.479.8800
Madison – 608.203.8500
Green Bay – 920.469.2110
Chippewa Valley – 715.861.6174
Rhinelander – 715.352.4091
Wausau – 715.803.6779
 

Latest News: Aducanumab Approved for Treatment of Alzheimer’s Disease

As the first FDA-approved drug that delays decline due to Alzheimer’s disease, the approval of aducanumab (Aduhelm™) is a victory for people living with Alzheimer’s and their families.
Learn More.